SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

11 Nov 2022 Evaluate
The Total revenue for the quarter ended September 2022 of  Rs. 14848.80 millions remain, more or less, the same.Net profit of the cmpany stood at Rs. 1677.80 millions for the quarter ended September 2022 a decline of -34.88% from Rs. 2576.40 millions  in the same quarter last year.A decline of 3085.30 millions was observed in the OP in the quarter ended September 2022 from 3740.90 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 14848.80 14238.40 4.29 29541.60 29024.40 1.78 53993.60 51391.60 5.06
Other Income 365.90 150.70 142.80 554.00 286.80 93.17 561.30 622.40 -9.82
PBIDT 3085.30 3740.90 -17.53 5847.90 7816.80 -25.19 12996.70 15758.20 -17.52
Interest 90.10 14.70 512.93 158.00 27.30 478.75 72.10 81.40 -11.43
PBDT 2995.20 3726.20 -19.62 5689.90 7789.50 -26.95 12924.60 15676.80 -17.56
Depreciation 549.20 505.00 8.75 1083.30 1004.60 7.83 2041.00 1877.20 8.73
PBT 2446.00 3221.20 -24.07 4606.60 6784.90 -32.11 10883.60 13799.60 -21.13
TAX 768.20 644.80 19.14 1490.60 1361.30 9.50 2174.20 2391.90 -9.10
Deferred Tax 26.70 83.00 -67.83 154.60 174.50 -11.40 201.40 -57.90 -447.84
PAT 1677.80 2576.40 -34.88 3116.00 5423.60 -42.55 8709.40 11407.70 -23.65
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 253.70 0.00
PBIDTM(%) 20.78 26.27 -20.92 19.80 26.93 -26.50 24.07 30.66 -21.50

Ipca Laboratories Share Price

1561.00 -2.70 (-0.17%)
07-May-2026 14:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.65
Dr. Reddys Lab 1311.25
Cipla 1368.70
Zydus Lifesciences 941.60
Lupin 2456.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×